Capella 4055 Assessment 4
Student Name
Capella University
NURS-FPX4055 Optimizing Population Health through Community Practice
Prof. Name
Date
Health Promotion Plan Presentation
Good morning, and thank you for joining us today. We are pleased to have our community partners present for this educational session focused on preventing Human Papillomavirus (HPV) infection among adolescents and young adults, specifically those between the ages of 11 and 26, in Schwenksville, Pennsylvania. The aim of today’s presentation is to enhance awareness about HPV and its connection to several cancers, highlight the benefits of early vaccination, and build skills for communicating effectively with healthcare providers and families about immunization. This initiative is guided by SMART goals previously co-developed with participants and aligned with the national objectives outlined in Healthy People 2030.
Presentation Roadmap
To ensure a structured and impactful session, today’s agenda is built around key educational and engagement milestones. First, we will review essential facts about HPV, including how it is transmitted and its strong association with various cancers. Next, we will discuss the HPV vaccine’s safety, effectiveness, and the importance of early immunization. We aim to support each participant in making a personal commitment to schedule vaccination within 30 days. Communication techniques for discussing the vaccine with healthcare providers and family members will also be introduced and practiced. Finally, participants will engage in activities, complete a post-session quiz, and provide feedback through a brief survey.
Key Information About HPV and Its Link to Cancer
HPV is among the most prevalent sexually transmitted infections, primarily spread through skin-to-skin sexual contact. While many infections clear on their own, persistent infection with high-risk HPV strains (notably types 16 and 18) can lead to severe health outcomes, including several forms of cancer. In Pennsylvania, vaccination rates remain suboptimal, with only 68.7% of adolescents fully vaccinated and even lower rates (48.7%) in rural areas like Schwenksville (PA.gov, 2025). This highlights the need for stronger public health outreach and intervention.
Long-term HPV infections may cause abnormal cellular changes that develop into cancers, particularly cervical, anal, penile, oropharyngeal, and genital cancers (Huber et al., 2021). Often, these infections show no early symptoms, underscoring the importance of preventive action through vaccination and regular health screenings. Immunization against HPV significantly reduces the likelihood of developing these cancers and represents a powerful cancer prevention strategy.
Table 1: HPV-Associated Cancers and Prevention through Vaccination
| Cancer Type | HPV Link | Vaccination Impact |
|---|---|---|
| Cervical Cancer | >90% caused by HPV | Early vaccination can prevent almost all cases |
| Anal and Penile Cancers | Linked to persistent HPV | Risk significantly lowered with immunization |
| Oropharyngeal Cancer | HPV-related in many cases | Vaccine reduces likelihood of oral HPV infection |
| Genital Warts | Caused by HPV types 6 and 11 | Vaccine prevents majority of genital wart cases |
Benefits of Timely HPV Vaccination
Timely administration of the HPV vaccine—preferably before sexual debut, around ages 11 or 12—offers strong, long-lasting protection. The younger the individual, the stronger the immune response, and the longer the protection persists. According to Hoes et al. (2021), early vaccination produces optimal immunogenicity and protects against multiple HPV-related diseases. Girls vaccinated before exposure to HPV have a significantly reduced lifetime risk of cervical cancer, the second most common cancer among women globally (Huber et al., 2021).
Beyond cervical cancer, the vaccine also lowers risks for anal, penile, and oropharyngeal cancers in both sexes. Additionally, it prevents the development of genital warts, which, though non-cancerous, often carry a psychological burden. Vaccination not only safeguards individuals but also builds community immunity. A high vaccination rate reduces HPV circulation, thereby protecting even those who are unvaccinated or immunocompromised (Xu et al., 2024).
Table 2: Key Benefits of Early HPV Vaccination
| Benefit | Explanation |
|---|---|
| Stronger Immune Response | Young immune systems produce more antibodies and retain protection longer |
| Cancer Prevention | Prevents cervical, anal, penile, and throat cancers |
| Genital Wart Reduction | Protects against strains causing genital warts |
| Community Immunity | Limits transmission, protecting unvaccinated individuals |
| Mental and Social Relief | Reduces stigma and emotional distress associated with HPV-related conditions |
Strategies for Discussing HPV Vaccination
Effective communication plays a pivotal role in increasing vaccine uptake. One approach is sharing accurate, evidence-based information from credible health authorities such as the CDC and WHO. Facts about vaccine safety and its proven cancer-preventive benefits provide a solid foundation for conversations.
Another helpful strategy involves asking thoughtful, informed questions. For instance, asking providers about the long-term health benefits of vaccination encourages open and informed discussions (Kassymbekova et al., 2023). Lastly, addressing myths head-on is crucial. A common misconception is that the vaccine encourages early sexual activity; however, its actual goal is to protect individuals from severe diseases, a fact healthcare providers can emphasize to reassure hesitant families.
Table 3: Communication Strategies for HPV Vaccine Advocacy
| Strategy | Application |
|---|---|
| Evidence-Based Facts | Use data and recommendations from trusted health organizations |
| Informed Questioning | Ask thoughtful questions to promote dialogue and clarify concerns |
| Myth Debunking | Address misconceptions calmly with factual counterpoints |
Developed SMART Goals with the Participants
The presentation was guided by SMART goals, developed to ensure measurable educational outcomes:
- Knowledge Acquisition: By the session’s end, 90% of participants should correctly identify at least three facts about HPV and its link to cancer.
- Vaccination Commitment: At least 80% of attendees should commit to scheduling the HPV vaccine within 30 days.
- Confidence Building: 85% of participants should feel confident discussing HPV vaccination with providers and family.
These goals not only reflect educational intent but also support community empowerment to act on health knowledge.
Session Evaluation on Developed SMART Goals
The session achieved high engagement and learning outcomes. In terms of knowledge, 92.5% of participants identified three or more key HPV facts, exceeding the first goal. However, only 75% of eligible attendees committed to scheduling their vaccine within 30 days—slightly under the 80% benchmark. Meanwhile, the third goal was met, with 85% expressing improved confidence in vaccine-related conversations.
Challenges included hesitation among younger participants and concerns about confronting vaccine myths. To address this, future sessions may include live family engagement, structured role-play scenarios for communication practice, and follow-up meetings for those needing more time to make decisions.
Session Evaluation on Healthy People 2030 Objectives
This initiative aligns closely with Healthy People 2030 objectives, particularly those aimed at increasing HPV vaccination rates and reducing HPV-related disease burden (U.S. Department of Health and Human Services, n.d.). The session significantly boosted knowledge and confidence, which are precursors to behavior change. However, the goal of early vaccine initiation was only partially met.
To more fully realize national objectives, future sessions should incorporate extended family discussions, stronger myth-busting modules, and follow-up communication to reinforce vaccine benefits. These enhancements could build trust and encourage action, improving HPV immunization uptake (Xu et al., 2024).
Conclusion
In conclusion, today’s session underscored the importance of HPV vaccination in preventing cancer and improving public health outcomes in Schwenksville, PA. Through education aligned with SMART goals and Healthy People 2030 objectives, participants gained essential knowledge, engaged in skill-building, and prepared to advocate for their health. While areas for improvement remain, especially in achieving higher commitment rates, we are optimistic that with targeted revisions, future sessions will yield even stronger public health outcomes and empower more families to make informed decisions.
References
Cheng, L., Wang, Y., & Du, J. (2020). Human papillomavirus vaccines: An updated review. Vaccines, 8(3), 391. https://doi.org/10.3390/vaccines8030391
Hoes, J., Pasmans, H., Schurink-van ’t Klooster, T. M., van der Klis, F. R. M., Donken, R., Berkhof, J., & de Melker, H. E. (2021). Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge. Human Vaccines & Immunotherapeutics, 18(1). https://doi.org/10.1080/21645515.2021.1908059
Capella 4055 Assessment 4
Huber, J., Mueller, A., Sailer, M., & Regidor, P.-A. (2021). Human papillomavirus persistence or clearance after infection in reproductive age. Women’s Health, 17, 174550652110207. https://doi.org/10.1177/17455065211020702
Kassymbekova, F., Zhetpisbayeva, I., Tcoy, E., Dyussenov, R., Davletov, K., Rommel, A., & Glushkova, N. (2023). Exploring HPV vaccine knowledge, attitudes, barriers and information sources among parents, health professionals and teachers in Kazakhstan: A mixed-methods study protocol. BMJ Open, 13(9), e074097. https://doi.org/10.1136/bmjopen-2023-074097
PA.gov. (2025). Dear VFC provider. https://www.pa.gov/content/dam/copapwp-pagov/en/health/documents/topics/documents/programs/immunizations/3.3.25%20-%202025%20HPV%20Call-to-Action%20Letter%20and%20Resources.pdf
U.S. Department of Health and Human Services. (n.d.). Vaccination – Healthy People 2030. Health.gov. https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination
Capella 4055 Assessment 4
Xu, M., Choi, J., Capasso, A., & DiClemente, R. (2024). Improving HPV vaccination uptake among adolescents in low-resource settings: Sociocultural and socioeconomic barriers and facilitators. Adolescent Health Medicine and Therapeutics, 15, 73–82. https://doi.org/10.2147/ahmt.s394119